
    
      This is a multi-center, open-label study of patients with previously treated stage I (IA and
      IB) or IIA MF who have not received a complete response after completing 12 months of
      treatment in clinical trial (2005NMMF-201-US)to either 0.02% MCH PG or 0.02% MCH in Aquaphor
      (AP) ointment formulations.
    
  